Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome

European Journal of Pharmacology

Volumn 295, Issue 2-3, 1996, Pages 123-129

  Tokuyama, Shogo ^a   Wakabayashi, Hiroyuki ^a   Ho, Ing K ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Butorphanol; Central nervous system; Glutamate; MK 801 (dizocilpine); Morphine; Opioid dependence

Indexed keywords

BUTORPHANOL; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; MORPHINE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE AGONIST; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; OPIATE ADDICTION; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

EID: 0030066154     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00645-1     Document Type: Article

References (38)

1. Abdelhamid, E.E., M. Sultana, P.S. Portoghese and A.E. Takemori, 1991, Selective blockade of delta-opioid receptors prevents the development of morphine tolerance and dependence in mice, J. Pharmacol. Exp. Ther. 258, 299.
2. Aghajanian, G.K., 1978, Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine, Nature 276, 186.
3. Aghajanian, G.K., J.H. Kogan and B. Moghaddam, 1994, Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study, Brain Res. 636, 126.
4. Ahtee, L., P. Attila, V. Lauhakangas, A. Solkinen and J. Sipila, 1987, The fall of homovanillic acid and 5-hydroxyindoleacetic acid concentrations in brain of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration, J. Neural Transm. 68, 63.
5. De la Baume, S., G. Patey, H. Marcais, P. Protais, J. Costentin and J.-C. Schwartz, 1979, Changes in dopamine receptors in mouse striatum following morphine treatments, Life Sci. 24, 2333.
6. Ennis, M. and G. Aston-Jones, 1988, Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brain, J. Neurosci. 8, 3644.
7. Feng, Y.Z., T. Zhang., R.W. Rockhold and I.K. Ho, 1994, Opioid receptor subtypes modurate pontine excitatory amino acid (EAA) levels differently in butorphanol and morphine dependence, Soc. Neurosci. Abstr. 20, 1232.
8. Feng, Y.Z., T. Zhang., R.W. Rockhold and I.K. Ho, 1995, Increased locus coeruleus glutamate levels are associated with naloxone-precipitated withdrawal from butorphanol in the rat, Neurochem. Res. 20, 675.
9. Goldstein, A. and A. Naidu, 1989, Multiple opioid receptors: ligand selectivity profiles and binding site signatures, Mol. Pharmacol. 36, 265.
10. 2 (CTOP) in mice, Eur. J. Pharmacol. 150, 355.
11. Honore, T., S.N. Davies, J. Drejer, E.J. Fletcher, P. Jacobsen, D. Lodge and F.E. Nielsen, 1988, Quinoxalinediones: potent, competitive non-NMDA glutamate receptor antagonist, Science 241, 701.
12. Horan, P.J. and I.K. Ho, 1989, Comparative pharmacological and biochemical studies between butorphanol and morphine, Pharmacol. Biochem. Behav. 34, 847.
13. Horan, P.J. and I.K. Ho, 1991, The physical dependence liability of butorphanol: a comparative study with morphine, Eur. J. Pharmacol. 203, 387.
14. Imperato, A., M.G. Scrocco, S. Bacchi and L. Angelucci, 1990, NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus, Eur. J. Pharmacol. 187, 555.
15. Jaw, S.P., B. Hoskins and I.K. Ho, 1993a, Involvement of δ-opioid receptors in physical dependence on butorphanol, Eur. J. Pharmacol. 240, 67.
16. Jaw, S.P., B. Hoskins and I.K. Ho, 1993b, Opioid antagonists and butorphanol dependence, Pharmacol. Biochem. Behav. 44, 497.
17. Jaw, S.P., M. Makimura, B. Hoskins and I.K. Ho, 1993c, Effect of nor-binaltorphimine on butorphanol dependence, Eur. J. Pharmacol. 239, 133.
18. Johnson, J.W. and P. Ascher, 1987, Glycine potentiates the NMDA response in cultured mouse brain neurons, Nature 325, 529.
19. Krebs, M.O., J.M. Desce, M.L. Kemel, C. Gauchy, G. Godeheu, A. Cheramy and J. Glowinski, 1991, Glutamate control of dopamine release in the rat striatum: evidence for presynaptic N-metyl-D-aspartate receptors on dopaminergic nerve terminals, J. Neurochem. 56, 81.
20. 3H]U-69,593 a highly selective ligand for the opioid kappa receptor, Eur. J. Pharmacol. 109, 281.
21. Lodge, D. and G. Collingridge, 1991, The pharmacology of excitatory amino acids: a TIPS special report, Trends Pharmacol. Sci. (Elsevier Trends Journals, Cambridge, UK).
22. Lutfy, K., D.E. Hurlbut and E. Weber, 1993, Blockade of morphine induced analgesia and tolerance in mice by MK-801, Brain Res. 616, 83.
23. Martin, W.R., 1984, Pharmacology of opioids, Pharmacol. Rev. 35, 283.
24. 2 opioid receptors in the development of morphine dependence in mice, J. Pharmacol. Exp. Ther. 264, 1141.
25. 3H]dopamine release from dissociated cell cultures of rat ventral mesencephalon, J. Neurochem. 52, 1300.
26. Oh, K.W., M. Makimura, S.P. Jaw, B. Hoskins and I.K. Ho, 1992, Effects of β-funaltrexamine on butorphanol dependence, Pharmacol. Biochem. Behav. 42, 29.
27. Paxinos, G. and C. Watson, 1986, The Rat Brain in Stereotaxic Coordinates, 2nd edn. (Academic Press, Orlando, FL).
28. Pircio, A.W., J.A. Gylys, R.L. Cavanagh, J.P. Buyniski and M.E. Bierwagen, 1976, The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic, Arch. Int. Pharmacodyn. Ther. 220, 231.
29. Rasmussen, K. and G.K. Aghajanian, 1989, Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis, Brain Res. 505, 346.
30. Redmond, Jr., D.E. and J.H. Krystal, 1984, Multiple mechanisms of withdrawal from opioid drugs, Annu. Rev. Neurosci. 7, 443.
31. Redmond, Jr., D.E., Y.H. Huang, D.R. Snyder and J.W. Maas, 1976, Behavioral effects of stimulation of the nucleus locus coeruleus in the stump-tailed monkey (Macaca arctoides), Brain Res. 116, 502.
32. Schoepp, D.D. and P.J. Conn, 1993, Metabolic glutamate receptors in brain function and pathology, Trends Pharmacol. Sci. 14, 13.
33. Tanganelli, S., T. Antonelli, M. Morari, C. Bianchi and L. Beani, 1991, Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs, Neurosci. Lett. 122, 270.
34. 2+ channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats, Eur. J. Pharmacol. 279, 93.
35. Tokuyama, S., Y.Z. Feng, H. Wakabayashi and I.K. Ho, 1995b, Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8, Eur. J. Pharmacol. 284, 101.
36. Trujillo, K. and H. Akil, 1991, Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801, Science 251, 85.
37. Watkins, J.C., P. Krogsgaard-Larsen and T. Honore, 1990, Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists, in: The Pharmacology of Excitatory Amino Acids. Tips Special Report, eds. D. Lodge and G. Collingridge (Elsevier, Cambridge) p. 4.
38. Zhang, T., Y.Z. Feng, R.W. Rockhold and I.K. Ho, 1994, Naloxone-precipitated morphine withdrawal increases pontaine glutamate levels in the rat, Life Sci. 55, 25.